Intervention
Dulaglutide
ClinicalTrials.gov intervention label
How to interpret these research links
Connected source recordsThis is the original ClinicalTrials.gov intervention label, found in 68 distinct published trials. Registry interventions may represent drugs, devices, procedures or other study activities. A matched term or study association does not establish product equivalence, efficacy or regulatory approval.
Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.
Advertisement
Clinical trials
60 shownA Study of Dulaglutide (LY2189265) 3.0 mg and 4.5 mg in Pediatric Participants With Type 2 Diabetes Mellitus (AWARD-PEDS PLUS)NCT06739122 · 2025-01-10
RECRUITINGTherapeutic Strategies for Microvascular Dysfunction in Type 1 DiabetesNCT05478707 · 2023-10-05
RECRUITINGPhase II Study of Switching From Dulaglutide to PG-102(MG12) in Type 2 Diabetes MellitusNCT07677891 · 2026-10-01
NOT_YET_RECRUITINGA Study of Orforglipron (LY3502970) Compared With Dulaglutide in Pediatric Participants With Type 2 DiabetesNCT07668336 · 2026-09-01
NOT_YET_RECRUITINGEfficacy and Safety of Triple Therapy With Dulaglutide, SGLT2 Inhibitors, and Finerenone in Chinese Adults With Type 2 Diabetes and Chronic Kidney DiseaseNCT07537088 · 2026-05-01
NOT_YET_RECRUITINGEmulation of the REWIND Cardiovascular Outcomes Trial in Healthcare Claims Data.NCT07417631 · 2026-02-03
COMPLETEDINcreTin-based thERapies for Cardiovascular Event PrevenTion in Patients With and Without ASCVD (INTERCEPT-ASCVD)NCT07417618 · 2026-01-27
COMPLETEDInjectable Semaglutide vs Dulaglutide in Individuals at Cardiovascular RiskNCT07619495 · 2026-01-20
COMPLETEDA Study to Evaluate the Effect of Fasting Duration and Dulaglutide (LY2189265) Withholding on Gastric Retention in Participants With Type 2 Diabetes MellitusNCT07313813 · 2025-12-29
COMPLETEDWeekly GLP-1 Receptor Agonists in Obese Individuals Without DiabetesNCT07834398 · 2025-11-14
COMPLETEDRole of Glucagon-like Peptide-1 Receptor Agonists in Menstrual Irregularities in Adolescent Females With Type 1 Diabetes MellitusNCT07319286 · 2025-08-04
ENROLLING_BY_INVITATIONImpact of Pharmacogenetic-Guided Treatment on Type 2 Diabetes.NCT06851962 · 2025-05-26
COMPLETEDComparative Study of Tirzepatide Versus Dulaglutide (SURPASS CVOT) or Semaglutide on Major Cardiovascular Events in Participants With Type 2 DiabetesNCT06779929 · 2024-11-01
COMPLETEDPrediction of the SURPASS-CVOT Cardiovascular Outcome Trial in Healthcare Claims DataNCT07088718 · 2024-10-01
COMPLETEDComparative Effectiveness of Tirzepatide and Semaglutide in Individuals at Cardiovascular RiskNCT07096063 · 2024-10-01
COMPLETEDA Phase 3 Study to Evaluate the Efficacy of JY09 Compared With Dulaglutide in Combination Therapy Diabetes Mellitus Type 2 Patients With MetforminNCT06257966 · 2024-07-17
ACTIVE_NOT_RECRUITINGA Study of TG103 Injection Combined With Metformin in Treatment of Type 2 Diabetes MellitusNCT06235086 · 2024-04-08
COMPLETEDA Study of HS-20094 in Patients With T2DMNCT06901648 · 2024-02-06
COMPLETEDEffect of Empagliflozin and Dulaglutide on MAFLD in Patients With T2DNCT05140694 · 2023-12-01
UNKNOWNA Phase 3 Study to Evaluate the Efficacy of XW003 Compared With Dulaglutide in Participants With T2DMNCT05680129 · 2023-01-10
COMPLETEDA Study of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes Mellitus in IndiaNCT05659537 · 2022-12-29
COMPLETEDA Study of Tirzepatide (LY3298176) in Adult Participants With Type 2 Diabetes Switching From Dulaglutide (SURPASS-SWITCH)NCT05564039 · 2022-11-30
COMPLETEDA Study of LY3532226 in Participants With Type 2 Diabetes MellitusNCT05407961 · 2022-06-07
COMPLETEDA Study of LY3457263 Alone and in Combination With Dulaglutide (LY2189265) in Participants With Type 2 DiabetesNCT05377333 · 2022-06-02
COMPLETEDBasal Plus GLP1-ra on Glycemic Variability in CKDNCT05218915 · 2022-01-28
COMPLETEDA Study of LY3502970 in Participants With Type 2 Diabetes MellitusNCT05048719 · 2021-09-15
COMPLETEDA Study of IBI362 in Chinese Patients With Type 2 DiabetesNCT04965506 · 2021-09-06
COMPLETEDA Study of LY3437943 in Participants With Type 2 DiabetesNCT04867785 · 2021-05-13
COMPLETEDThe Effects of Glucose Control and Weight Loss Between Beinaglutide and Dulaglutide in Type 2 Diabetes With Overweight or Obesity.NCT05005741 · 2021-05-01
UNKNOWNA Study of Two Doses of Dulaglutide (LY2189265) in Japanese Patients With Type 2 DiabetesNCT04809220 · 2021-04-13
COMPLETEDA Study of Dulaglutide (LY2189265) in Chinese Participants With Type 2 DiabetesNCT04591626 · 2020-12-07
COMPLETEDA Study of LY3457263 in Healthy Participants and Participants With Type 2 DiabetesNCT04641312 · 2020-11-25
COMPLETEDMultiple-dose Tolerability and Pharmacokinetic of IBI362 in Chinese Patients With T2DMNCT04466904 · 2020-09-12
COMPLETEDA Study of LY3493269 in Participants With Type 2 DiabetesNCT04515576 · 2020-08-25
COMPLETEDA Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 DiabetesNCT04255433 · 2020-05-29
COMPLETEDEfficacy and Safety of iGlarLixi Versus Insulin Glargine Plus Dulaglutide in Patients With Type 2 DiabetesNCT04893148 · 2020-05-26
UNKNOWNGLP-1 Therapy: The Role of IL-6 Signaling and Adipose Tissue Remodeling in Metabolic ResponseNCT04387201 · 2020-05-15
COMPLETEDDulaglutide Versus Liraglutide in Obese Type 2 Diabetic Adolescents Using MetforminNCT04829903 · 2020-01-02
COMPLETEDA Study of LY3437943 in Participants With Type 2 Diabetes Mellitus (T2DM)NCT04143802 · 2019-12-18
COMPLETEDComparison of Injection Site Pain Experience for Semaglutide and Dulaglutide scNCT04189848 · 2019-12-03
COMPLETEDA Study of Tirzepatide (LY3298176) Compared to Dulaglutide in Participants With Type 2 DiabetesNCT03861052 · 2019-05-07
COMPLETEDDulaglutide and Insulin MicrosecretiON in Type 1 DiabetesNCT03668470 · 2019-01-31
COMPLETEDEffect of Dulaglutide on Liver Fat in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver DiseaseNCT03590626 · 2019-01-01
COMPLETEDEfficacy and Safety of Efpeglenatide Versus Dulaglutide in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With MetforminNCT03684642 · 2018-09-26
TERMINATEDNovel Antidiabetic Medications and Their Effect on Liver Steatosis (NAMELS-18)NCT05946148 · 2018-06-01
COMPLETEDA Study of the Efficacy and Safety of Dulaglutide (LY2189265) in Participants With Type 2 DiabetesNCT03495102 · 2018-04-05
COMPLETEDThe Effect of Combined Dulaglutide and Dapagliflozin Treatment vs DPP-4 Inhibitors in Endothelial and Vascular Function in Patients With Type 2 Diabetes Mellitus and AlbuminuriaNCT06611904 · 2018-02-01
UNKNOWNEffect of Exenatide LAR or Dulaglutide on the Variability of 24-hour Heart Rate and Blood Pressure in Type 2 DiabetesNCT03444142 · 2017-11-17
UNKNOWNA Study of the Glucodynamic Effects of Dulaglutide (LY2189265) in Japanese Participants With Type 2 DiabetesNCT03315780 · 2017-10-28
COMPLETEDA Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes MellitusNCT03131687 · 2017-05-24
COMPLETEDDulaglutide in Diabetic Patients, Relationship Between Arterial Stiffness, Endothelial Function, Clinical and Laboratory VariablesNCT03824002 · 2017-04-01
COMPLETEDSafety and Efficacy of Oral Semaglutide Versus Dulaglutide Both in Combination With One OAD (Oral Antidiabetic Drug) in Japanese Subjects With Type 2 DiabetesNCT03015220 · 2017-01-10
COMPLETEDA Study of Dulaglutide (LY2189265) in Children and Adolescents With Type 2 DiabetesNCT02963766 · 2016-12-29
COMPLETEDA Study of Investigational Dulaglutide Doses in Participants With Type 2 Diabetes on Metformin MonotherapyNCT02973100 · 2016-12-01
COMPLETEDA Study of Dulaglutide in Japanese Participants With Type 2 DiabetesNCT02750410 · 2016-08-01
COMPLETEDA Study of Tirzepatide (LY3298176) in Healthy Participants and Participants With Type 2 Diabetes (T2DM)NCT02759107 · 2016-05-11
COMPLETEDEfficacy and Safety of Semaglutide Versus Dulaglutide as add-on to Metformin in Subjects With Type 2 Diabetes.NCT02648204 · 2016-01-06
COMPLETEDA Study of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes MellitusNCT02597049 · 2015-11-01
COMPLETEDA Study of Dulaglutide (LY2189265) in Participants With Type II DiabetesNCT02152371 · 2014-05-01
COMPLETEDStudy of How Dulaglutide Compares to Placebo in Participants With Type 2 Diabetes Who Are Also on Sulfonylurea Therapy (AWARD-8)NCT01769378 · 2013-01-01
COMPLETEDCommon conditions
Type 2 Diabetes21Diabetes Mellitus, Type 219Type 2 Diabetes Mellitus12Overweight4Diabetes Mellitus3Obesity3Type 2 Diabetes Mellitus (T2DM)3Cardiovascular (CV) Risk2Diabetes2Healthy2Healthy Volunteers2Type2 Diabetes Mellitus2Adiposity1Adolescent Obesity1Adult Subjects With Type1Diabetes and Insulin Microsecretion1Arterial Stiffness1ASCVD1Cardiovascular Disease1Chronic Kidney Disease1CKD - Chronic Kidney Disease1Diabetes Mellitus Type 21Diabetes Mellitus, Type 11Diabetic Kidney Disease1Drug Effect1Endocrine System Diseases1
Leading sponsors
Eli Lilly and Company34Brigham and Women's Hospital6Novo Nordisk A/S3Innovent Biologics (Suzhou) Co. Ltd.2AdventHealth Translational Research Institute1Ain Shams University1Attikon Hospital1Beijing Dongfang Biotech Co., Ltd.1Chungbuk National University Hospital1Corporacion Parc Tauli1CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.1Elaine Chow1First Affiliated Hospital of Wannan Medical College1Fundación para la Investigación del Hospital Clínico de Valencia1Hangzhou Sciwind Biosciences Co., Ltd.1
Trial status mix
COMPLETED55
UNKNOWN5
NOT_YET_RECRUITING3
RECRUITING2
ACTIVE_NOT_RECRUITING1
ENROLLING_BY_INVITATION1
TERMINATED1
Phase mix
PHASE322
PHASE414
PHASE113
PHASE211
NA3
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.